Conatus Pharmaceuticals Inc. (CNAT) Analysts See $-0.14 EPS as of March, 6

During Q3 2018 the big money sentiment increased to 0.62. That’s change of 0.06, from 2018Q2’s 0.56. 11 investors sold all, 18 reduced holdings as Conatus Pharmaceuticals Inc. ratio improved. 9 rose holdings while 9 funds bought holdings. Funds hold 8.97 million shares thus 3.85% less from 2018Q2’s 9.33 million shares.
Tower Research Capital Lc (Trc) reported 557 shs or 0% of all its holdings. Group Inc One Trading Limited Partnership holds 0.01% in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) or 239,928 shs. Bluecrest Mngmt Limited owns 36,140 shs for 0.01% of their capital. Sectoral Asset Management has invested 0.01% of its capital in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Susquehanna Intll Grp Limited Liability Partnership holds 195,697 shs. Courage Management Limited Liability Co holds 0.47% or 150,050 shs. Citadel Advisors Llc, a Illinois-based fund reported 63,951 shs. Acadian Asset Mngmt owns 180,574 shs. Wells Fargo And Company Mn holds 0% or 26,183 shs in its capital. Qs Ltd Liability Company holds 0.01% or 96,807 shs in its capital. Royal Bank Of Canada invested in 700 shs or 0% of the stock. Gsa Partners Ltd Liability Partnership holds 19,721 shs. Deutsche Commercial Bank Ag holds 0% or 1,761 shs in its capital. Utd Capital Advisers Ltd Llc owns 200,076 shs for 0.01% of their capital. Reilly Financial Lc holds 0.02% or 22,011 shs.

On March, 6 is awaited Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)’s earnings report, according to RTT. Analysts predict $-0.14 EPS, which is $0.01 up or 6.67 % from 2018’s $-0.15 EPS. -6.67 % EPS growth is what Wall Street’s forecasts after $-0.15 reported EPS previous quarter. CNAT reached $1.99 during the last trading session after $0.02 change.Currently Conatus Pharmaceuticals Inc. is downtrending after 62.59% change in last February 12, 2018. CNAT has 306,629 shares volume. CNAT underperformed by 62.59% the S&P 500.

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States.The company has $60.22 million market cap. The Company’s product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response.Last it reported negative earnings.

For more Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) news brought out recently go to: Seekingalpha.com, Nasdaq.com, Globenewswire.com, Seekingalpha.com or Globenewswire.com. The titles are as follows: “Conatus’ Failure Was A Blow, But The Most Important Study Is Yet To Come – Seeking Alpha” brought out on December 17, 2018, “No Respite For MiMedx, CNAT Fails NASH Trial, NDRA On Watch – Nasdaq” on December 06, 2018, “Conatus Pharmaceuticals Announces Three Accepted Abstracts for AASLD Annual Meeting – GlobeNewswire” with a publish date: October 02, 2018, “Conatus up 6% premarket on publication of emricasan data – Seeking Alpha” and the last “Conatus Pharmaceuticals to Participate in Upcoming Investor Conferences – GlobeNewswire” with publication date: September 19, 2018.

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.